

## Antileishmanial polyphenols from *Corymbia maculata*

JASMEEN SIDANA<sup>a,†</sup>, DINESH NEERADI<sup>b</sup>, ALKA CHOUDHARY<sup>a</sup>, SUSHMA SINGH<sup>b</sup>, WILLIAM J FOLEY<sup>c</sup> and INDER PAL SINGH<sup>a,\*</sup>

<sup>a</sup>Department of Natural Products, <sup>b</sup>Department of Biotechnology, National Institute of Pharmaceutical Education and Research (NIPER), Sector–67, SAS Nagar, Punjab 160 062, India

<sup>c</sup>Research School of Biology, The Australian National University, Canberra 0200, Australia

<sup>†</sup>Present address: School of Pharmaceutical Sciences, Lovely Professional University, Phagwara, Punjab 114 441, India

e-mail: ipsingh@niper.ac.in; ipsingh67@yahoo.com

MS received 5 December 2012; revised 22 February 2013; accepted 5 April 2013

**Abstract.** An activity-guided fractionation was used to identify the antileishmanial compounds of *Corymbia maculata*. The hexane, ethyl acetate and methanol extracts were active in *in vitro* antileishmanial assay. Twelve polyphenols including 8-demethyl eucalyptin (**1**), eucalyptin (**2**), myrciaphenone A (**3**), myrciaphenone B (**4**), quercetin-3-*O*- $\beta$ -D-xylopyranoside (**5**), myricetin-3-*O*- $\alpha$ -L-rhamnopyranoside (**6**), quercetin-3-*O*- $\beta$ -D-galactopyranoside (**7**), quercetin-3-*O*- $\beta$ -D-glucopyranoside (**8**), quercetin-3-*O*- $\alpha$ -L-rhamnopyranoside (**9**), syringic acid (**10**), gallic acid-3-methyl ether (**11**), gallic acid-4-methyl ether (**12**) and gallic acid (**13**) were isolated from the active extracts. All the tested compounds except 8-demethyleucalyptin and myrciaphenone B showed strong to moderate (6.9–24.5  $\mu$ M) antileishmanial activity against *Leishmania donovani* promastigotes. An HPLC-PDA method has been developed to detect/quantify 29 compounds in the extracts of *C. maculata* leaves. This validated method allows simultaneous quantitation of seven flavonoids, fourteen phloroglucinols and eight other polyphenols and can be applied for qualitative as well as quantitative determination of phytoconstituents in *Eucalyptus* matrices.

**Keywords.** *Corymbia maculata*; flavonoid glycosides; methylated flavonoids; myrciaphenone; HPLC quantitation.

### 1. Introduction

Leishmaniasis, one of the world's most neglected diseases, is endemic in 88 countries with more than 350 million people at risk.<sup>1</sup> During the last few years, we have focused our interest on isolation and synthesis of potential antileishmanial molecules.<sup>2–4</sup> In search of more bioactive constituents, we have investigated *Corymbia maculata* (Hook.) K D Hill and L A S Johnson (Syn: *Eucalyptus maculata*). Though several members of this genus have been the subject of extensive phytochemical and pharmacological research, reports of investigations on *C. maculata* are very few. Some methylated flavonoids isolated from *C. maculata* leaf extracts have shown antibacterial activity.<sup>5</sup>

In this paper, we report isolation of flavonoids and phenolics including 8-demethyl eucalyptin (**1**),<sup>6</sup> eucalyptin (**2**),<sup>6</sup> myrciaphenone A (**3**),<sup>7</sup> myrciaphenone B (**4**),<sup>8</sup> quercetin-3-*O*- $\beta$ -D-xylopyranoside (**5**),<sup>9</sup>

myricetin-3-*O*- $\alpha$ -L-rhamnopyranoside (**6**),<sup>10</sup> quercetin-3-*O*- $\beta$ -D-galactopyranoside (**7**),<sup>9</sup> quercetin-3-*O*- $\beta$ -D-glucopyranoside (**8**),<sup>9</sup> quercetin-3-*O*- $\alpha$ -L-rhamnopyranoside (**9**),<sup>9</sup> syringic acid (**10**),<sup>11</sup> gallic acid-3-methyl ether (**11**),<sup>12</sup> gallic acid-4-methyl ether (**12**)<sup>13</sup> and gallic acid (**13**)<sup>14</sup> (figure 1) from the extracts of leaves of *C. maculata*.

In addition, an RP-HPLC method was developed to detect and/or quantify formylated phloroglucinols and other compounds including flavonoids and simple phenols in the extracts of *C. maculata*. Although there have been several studies of the chemosystematics of the genus *Eucalyptus*, there are very few analytical methods available to simultaneously determine (qualitatively or quantitatively) the compounds belonging to diverse structural categories. The proposed HPLC method enables determination of eight formylated phloroglucinol compounds (including two monomeric, one dimeric and five euglobals), six 'non-formylated' phloroglucinols (including a monomer, two phloroglucinol glycosides and three triketones), seven flavonoids and eight other polyphenols.

\*For correspondence  
NIPER communication no. 492.

## 2. Materials and methods

### 2.1 General

All chemicals and solvents used for extraction and purification were of laboratory reagent grade. All chromatographic purifications were performed with silica gel #60–120 and silica gel G whereas all TLC analysis was performed on silica gel coated (Merck Kieselgel 60 F<sub>254</sub>, 0.2 mm thickness) plates. HPLC grade ethyl acetate, acetonitrile, methanol, formic acid, acetic acid and trifluoroacetic acid (JT Baker) and ultra pure water (Elga®) were used for sample preparation and in HPLC mobile phases.

Apart from the chemical markers isolated from *C. maculata* (**1–13**), the standards i.e., protocatechuic acid (**14**), chlorogenic acid (**15**), caffeic acid (**16**),

2-hydroxycinnamic acid (**17**) were a kind gift from Prof. R C Gupta of University of Louisville, USA. Miniatone (**20**), grandinol (**21**), 8-demethyl kalmiatin (**22**), jensenone (**23**), euglobal G1 (**25**), sideroxylonal A (**26**), euglobal G2 (**27**), euglobal BI-1 (**28**), euglobal G3 (**29**), euglobal G4 (**30**) were isolated from different sources.<sup>4,15</sup> Syncarpic acid (**18**), flavesone (**19**) and leptospermone (**24**) were synthesized from phloroglucinol (for structures, see figure 1). All the standards were ≥98% pure by HPLC and NMR.

### 2.2 Plant material

The plant material was collected from four individual trees at the Australian National University coastal campus Kioloa, New South Wales, Australia. The leaves




Figure 1. Structures of compounds 1–30.

were air-dried in the shade, crushed coarsely and stored at  $-20^{\circ}\text{C}$  until extraction.

### 2.3 Equipment and apparatus

The HPLC analysis was carried out on  $\text{C}_{18}$  column (Phenomenex,  $250 \times 4.6$  mm,  $5 \mu$ ,  $100 \text{ \AA}$ ) connected to a Shimadzu HPLC system consisting of a model LC-10AT VP fitted with a SIL-20AC autosampler and SPD-M10A VP photodiode array detector. Princeton SPHER- $\text{C}_{18}$  column ( $250 \times 10$  mm,  $5 \mu$ ,  $100 \text{ \AA}$ ) was used for isolation of compounds.

Isolation of compounds was also done using  $\text{C}_{18}$  column (Luna,  $250 \times 30$  mm,  $10 \mu$ ,  $100 \text{ \AA}$ ) connected to a preparative HPLC system (Shimadzu, CBM-20A) equipped with a LC-8A binary gradient pump, an SPD-20AV UV-Vis detector, an FRC-10A fraction collector and a recycle valve.

IR spectra were taken on FT-IR spectrometer (Nicolet, USA). Mass spectra were recorded on a GCMS-QS (Shimadzu, Japan).  $^1\text{H}$  and  $^{13}\text{C}$  NMR spectra were recorded on 400 and 100 MHz spectrometers (Bruker), respectively.

### 2.4 Extraction and isolation

Dried and crushed leaves (2 kg) of *C. maculata* were extracted in a macerator (20 L capacity) with hexane ( $5 \text{ L} \times 5$ ) for 48 h. The extract was filtered to remove any plant particles and was concentrated on rotary evaporator to yield 47 g of thick yellowish-green tar. Similarly, leaves were sequentially extracted with solvents in increasing polarity to yield 42 g of dichloromethane, 56 g of ethyl acetate and 80 g of methanol extract.

Light yellow crystals separated out of hexane extract while it was being concentrated. These were washed several times with cold hexane and dried. This fraction (7.8 g) showed only one major spot apart from chlorophylls on normal phase TLC developed with hexane-DCM (1:1). It was subjected to charcoal treatment to remove plant pigments. A portion (100 mg) of this fraction was subjected to semi-preparative HPLC [column:  $\text{C}_{18}$ ,  $250 \times 10$  mm; mobile phase: methanol-0.3% aqueous trifluoroacetic acid (9:1); Flow rate:  $3.5 \text{ mL}\cdot\text{min}^{-1}$ ; detection: 328 nm] to yield compound **1** (17 mg) and compound **2** (52 mg).

Methanol extract (80 g) was partitioned into dichloromethane (trace), ethyl acetate (20 g) and butanol (55 g) soluble fractions. The butanol-soluble fraction was chromatographed over silica gel #60-120 [column H: 30 cm, i.d.: 7 cm; eluant: hexane-ethyl

acetate (0% to 90% EtOAc) then chloroform-methanol gradients (1% to 50% MeOH)] to yield 15 sub-fractions.

Pooled sub-fractions 5 and 6 (6.3 g, eluted with 5-10% methanol in chloroform) were subjected to gel permeation chromatography over Sephadex LH20 using methanol to obtain six pools of different TLC profiles. Pools 3 and 4 (1.0 g) were subjected to recycle prep-HPLC [column:  $\text{C}_{18}$ ,  $250 \times 30$  mm; mobile phase: methanol-water-acetic acid (30:69:1); flow rate:  $40 \text{ mL}\cdot\text{min}^{-1}$ ; detection: 284 nm] to obtain compounds **3** (880 mg) and **4** (18 mg). Pool 5 (800 mg) stained yellow to orange with natural products (NP) reagent revealing the presence of flavonoids. Repetitive and recycle chromatography of this fraction [column:  $\text{C}_{18}$ ,  $250 \times 30$  mm; mobile phase: methanol-water-acetic acid (40:59:1); flow rate:  $40 \text{ mL}\cdot\text{min}^{-1}$ ; detection: 350 nm] gave compounds **5** (17 mg), **6** (55 mg), **7** (20 mg), **8** (5 mg) and **9** (145 mg).

Pooled sub-fractions 8 and 9 (16.3 g, eluted with 20% methanol in chloroform) were subjected to gel permeation chromatography over Sephadex LH20 using methanol to obtain 5 fractions. Fraction 3 (2.95 g) presented two major spots (giving intense blue fluorescence with NP reagent) on normal phase TLC developed with toluene-ethyl acetate-acetic acid (5:4.5:0.5). A portion of this fraction was rechromatographed over Sephadex LH20 using methanol-water (1:1) to yield compounds **10** (25 mg), **11** (48 mg), **12** (13 mg) and **13** (1.1 g).

**2.4a Compound 1:** Light yellow crystals, IR (Neat):  $\nu_{\text{max}}$  3391, 2923, 2953, 2868, 1605, 1459, 1376, 1219,  $1054 \text{ cm}^{-1}$ ; APCI MS:  $m/z$  313  $[\text{M}+1]^+$ , 298, 236, 165;  $^1\text{H}$  and  $^{13}\text{C}$  NMR (400 MHz,  $\text{CDCl}_3$ ): see table 1a.

**2.4b Compound 2:** Light yellow needles; IR (Neat):  $\nu_{\text{max}}$  3400, 2924, 2851, 1634, 1459, 1376, 1219,  $1053 \text{ cm}^{-1}$ ; APCI MS:  $m/z$  327  $[\text{M}+1]^+$ , 313  $[\text{M}-\text{CH}_3]^+$ , 236, 165;  $^1\text{H}$  and  $^{13}\text{C}$  NMR (400 MHz,  $\text{CDCl}_3$ ): see table 1a.

**2.4c Compound 3:** Off white solid; IR (Neat):  $\nu_{\text{max}}$  3368, 2946, 2833, 1654, 1453, 1414, 1114, 1032,  $668 \text{ cm}^{-1}$ ; APCI MS:  $m/z$  353  $[\text{M}+\text{Na}]^+$ , 316, 302, 202  $[\text{sugar}+\text{Na}]^+$ , 168;  $^1\text{H}$  and  $^{13}\text{C}$  NMR (400 MHz,  $\text{CD}_3\text{OD}$ ): see table 1a.

**2.4d Compound 4:** Light brown solid; IR (Neat):  $\nu_{\text{max}}$  3435, 2973, 2923, 2866, 1638, 1360, 1054,  $1033, 1016, 766 \text{ cm}^{-1}$ ; APCI MS:  $m/z$  505  $[\text{M}+\text{Na}]^+$ ,

**Table 1a.**  $^1\text{H}$  ( $\delta$  ppm, multiplicity,  $J$  in Hz) and  $^{13}\text{C}$  ( $\delta$  ppm) NMR data of compounds **1–4**.

Position	<b>1</b>		<b>2</b>		<b>3</b>		<b>4</b>	
	$\delta_{\text{C}}$	$\delta_{\text{H}}$	$\delta_{\text{C}}$	$\delta_{\text{H}}$	$\delta_{\text{C}}$	$\delta_{\text{H}}$	$\delta_{\text{C}}$	$\delta_{\text{H}}$
1					105.3		105.5	
2	163.4		162.6		164.8		161.2	
3	105.3	6.59, s	107.4	6.61, s	100.6	6.18, d, 2.0	94.3	6.16, s
4	182.4		183.2		166.3		165.0	
5	158.5		157.3		93.9	5.94, d, 2.0	97.0	5.94, s
6	114.1		114.1		161.2		166.2	
7	163.6		163.9		203.4		203.4	
8	89.3	6.49, s	104.1		32.1	2.68, s	32.0	2.67, s
9	155.9		152.9					
10	109.1		108.8					
1'	123.8		123.9		96.7	5.01, d, 7.4	100.8	5.07, d, 7.6
2'	127.9	7.84, d, 8.0	127.9	7.86, d, 8.4	73.3	3.72, dd, 12.0, 5.2	73.3	3.75–3.48, m
3'	114.5	7.01, d, 8.8	114.5	7.02, d, 8.4	77.1	3.55–3.34, m	76.8	
4'	162.5		162.6		69.7		69.7	
5'	114.5	7.01, d, 8.8	114.5	7.02, d, 8.4	76.9		74.4	
6'	127.9	7.84, d, 8.0	127.9	7.86, d, 8.4	60.9	3.91, dd, 12.0, 1.6	62.9	4.55, d, 12.0 and 4.45, dd, 12.0, 4.4
1''							119.8	
2''							108.8	7.10, s
3''							145.1	
4''							138.5	
5''							145.1	
6''							108.8	7.10, s
7''							166.9	
7/4'–OCH <sub>3</sub>	55.9/55.5	3.89/3.92, s	60.5/55.5	3.89/3.79, s				
6/8–CH <sub>3</sub>	7.3	2.11, s	8.5/8.2	2.39/2.21, s				

482 [M]<sup>+</sup>, 315;  $^1\text{H}$  and  $^{13}\text{C}$  NMR (400 MHz, CD<sub>3</sub>OD): see table 1a.

MS:  $m/z$  487 [M+Na]<sup>+</sup>, 465 [M+1]<sup>+</sup>, 303 [M-sugar]<sup>+</sup>;  $^1\text{H}$  and  $^{13}\text{C}$  NMR (400 MHz, CD<sub>3</sub>OD): see table 1b.

2.4e **Compound 5**: Yellow solid; IR (Neat):  $\nu_{\text{max}}$  3411, 2950, 2844, 1642, 1053, 1032, 1016 cm<sup>-1</sup>; APCI MS:  $m/z$  457 [M+Na]<sup>+</sup>, 303 [M-sugar]<sup>+</sup>;  $^1\text{H}$  and  $^{13}\text{C}$  NMR (400 MHz, CD<sub>3</sub>OD): see table 1b.

2.4i **Compound 9**: Light yellow solid; IR (Neat):  $\nu_{\text{max}}$  3435, 2972, 2844, 1645, 1372, 1054, 1032, 1015, 772 cm<sup>-1</sup>; APCI MS:  $m/z$  471 [M+Na]<sup>+</sup>, 449 [M+H]<sup>+</sup>, 303 [M-sugar]<sup>+</sup>;  $^1\text{H}$  and  $^{13}\text{C}$  NMR (400 MHz, CD<sub>3</sub>OD): see table 1b.

2.4f **Compound 6**: Light yellow solid; IR (Neat):  $\nu_{\text{max}}$  3368, 2946, 2833, 1654, 1453, 1415, 1116, 1031, 667 cm<sup>-1</sup>; APCI MS:  $m/z$  487 [M+Na]<sup>+</sup>, 464 [M]<sup>+</sup>, 319 [M-sugar]<sup>+</sup>;  $^1\text{H}$  and  $^{13}\text{C}$  NMR (400 MHz, CD<sub>3</sub>OD): see table 1b.

2.4j **Compound 10**: Colourless needles (MeOH); IR (Neat):  $\nu_{\text{max}}$  3474, 2941, 1698, 1617, 1521, 1372, 1203, 1177, 1113 cm<sup>-1</sup>; APCI MS:  $m/z$  181 [M–OH]<sup>+</sup>, 154;  $^1\text{H}$  NMR (400 MHz, CD<sub>3</sub>OD):  $\delta$  7.33 (2H, s, H–2, –6), 3.88 (6H, s, 3, 5–OCH<sub>3</sub>);  $^{13}\text{C}$  NMR (100 MHz, CD<sub>3</sub>OD):  $\delta$  170.1 (–COOH), 148.8 (C–3, –5), 141.7 (C–4), 121.9 (C–1), 108.3 (C–2, –6), 56.8 (3, 5–OCH<sub>3</sub>).

2.4g **Compound 7**: Yellow solid; IR (Neat):  $\nu_{\text{max}}$  3433, 2920, 1745, 1683, 1598, 1053, 1075 cm<sup>-1</sup>; APCI MS:  $m/z$  487 [M+Na]<sup>+</sup>, 465 [M+1]<sup>+</sup>, 303 [M-sugar]<sup>+</sup>;  $^1\text{H}$  and  $^{13}\text{C}$  NMR (400 MHz, CD<sub>3</sub>OD): see table 1b.

2.4k **Compound 11**: Light yellow needles (MeOH); IR (Neat):  $\nu_{\text{max}}$  3434, 2920, 1660, 1613, 1346, 1313, 1255, 1111, 1082 cm<sup>-1</sup>; APCI MS:  $m/z$  167 [M–OH]<sup>+</sup>;  $^1\text{H}$  NMR (400 MHz, CD<sub>3</sub>OD):  $\delta$  7.11 (1H, s, H–2),

2.4h **Compound 8**: Yellow solid; IR (Neat):  $\nu_{\text{max}}$  3433, 2920, 1745, 1683, 1598, 1053, 1075 cm<sup>-1</sup>; APCI

**Table 1b.**  $^1\text{H}$  ( $\delta$  ppm, multiplicity,  $J$  in Hz) and  $^{13}\text{C}$  NMR ( $\delta$  ppm) data of compounds 5–9.

Position	5		6		7		8		9	
	$\delta_{\text{C}}$	$\delta_{\text{H}}$	$\delta_{\text{C}}$	$\delta_{\text{H}}$	$\delta_{\text{C}}$	$\delta_{\text{H}}$	$\delta_{\text{C}}$	$\delta_{\text{H}}$	$\delta_{\text{C}}$	$\delta_{\text{H}}$
2	157.0		158.0		156.7		158.5		157.1	
3	134.0		134.9		133.9		135.7		134.8	
4	178.0		178.2		177.9		179.5		179.6	
5	161.6		161.8		156.6		159.1		157.9	
6	98.5	6.20, s	98.4	6.19, s	99.1	6.22, s	100.0	6.22, s	98.4	6.20, s
7	164.6		164.5		164.6		166.0		164.5	
8	93.3	6.39, s	93.3	6.36, s	93.9	6.43, s	94.9	6.42, s	93.3	6.37, s
9	157.5		157.1		161.7		162.9		161.8	
10	104.2		104.4		104.3		105.7		104.5	
1'	121.6		120.5		121.5		123.1		121.4	
2'	114.6	7.58, d, 8.8	108.1	7.00, s	115.6	7.84, s	116.1	7.71, s	114.9	7.33, s
3'	144.6		145.4		145.3		145.9		145.0	
4'	148.5		136.5		148.9		149.9		148.4	
5'	115.8	6.86, d, 8.4	145.4		116.4	6.88, d, 8.8	117.7	6.88, d, 8.4	115.5	6.90, d, 8.0
6'	121.9	7.61, s	108.1	7.00, s	122.4	7.59, d, 8.7	123.3	7.59, d, 8.4	121.5	7.30, d, 8.4
1''	103.2	5.17, d, 7.2	102.2	5.32, s	102.2	5.17, d, 8.0	104.5	5.24, d, 7.2	102.1	5.34, s
2''	73.8	3.51–3.41, m	70.5	4.23, s	71.6	3.56, m	75.8	3.47–3.35, m	70.5	4.21, s
3''	69.6		70.6	3.79, d, 8.4	76.3		78.4		70.6	3.74, dd, 9.2, 1.2
4''	76.1		71.9	3.34, m	68.4	3.48, m	71.3		71.8	3.45–3.38, m
5''	65.8	3.78, dd, 11.5, 5.1 and 3.10, m	70.7	3.52, m	73.6	3.35, m	78.1	3.22, m	70.7	
6''			16.3	0.98, d, 6.4	60.6	3.83, m and 3.64, m	62.6	3.73, m and 3.57, m	16.2	0.94, d, 6.0

7.09 (1H, s, H-6), 3.78 (3H, s, 3-OCH<sub>3</sub>);  $^{13}\text{C}$  NMR (100 MHz, CD<sub>3</sub>OD):  $\delta$  170.4 (–COOH), 149.1 (C–3), 146.1 (C–5), 140.5 (C–4), 121.9 (C–1), 112.2 (C–6), 106.3 (C–2), 56.8 (3-OCH<sub>3</sub>).

2.4l **Compound 12**: Light yellow needles (MeOH); IR (Neat):  $\nu_{\text{max}}$  3374, 1698, 1613, 1535, 1443, 1329, 1260, 1212, 1053 cm<sup>–1</sup>; APCI MS:  $m/z$  167 [M–OH]<sup>+</sup>;  $^1\text{H}$  NMR (400 MHz, CD<sub>3</sub>OD):  $\delta$  7.03 (2H, s, H–2, –6), 3.80 (3H, s, 4-OCH<sub>3</sub>);  $^{13}\text{C}$  NMR (100 MHz, CD<sub>3</sub>OD):  $\delta$  169.1 (–COOH), 146.5 (C–3, –5), 139.8 (C–4), 121.4 (C–1), 110.1 (C–2, –6), 52.4 (4-OCH<sub>3</sub>).

2.4m **Compound 13**: Off white solid; APCI MS  $m/z$  169 [M–H]<sup>+</sup>,  $^1\text{H}$  NMR (400 MHz, CD<sub>3</sub>OD,  $\delta$  ppm): 7.05 (s, 2H);  $^{13}\text{C}$  NMR (75 MHz, CD<sub>3</sub>OD,  $\delta$  ppm): 172.4, 145.1, 138.3, 120.4, 108.6.

## 2.5 *In vitro* antileishmanial activity

The MTT viability assay was performed as described previously.<sup>16</sup> Briefly, approximately  $2 \times 10^5$  *L. donovani* promastigotes were plated in 200  $\mu\text{L}$  of RPMI-1640 media (pH 7.2) in a flat-bottom 96-well culture microplate. Plate was incubated for 48 h at 24°C. Compounds were added to the wells at different

concentrations and the plate was again incubated for 48 h at 24°C. MTT solution was added to each well to a final concentration of 400  $\mu\text{g}/\text{mL}$ , and the plates were incubated for 3–4 h at 37°C. Cells were centrifuged at 3,000  $g$  for 10 min. Pellets were dissolved in 150  $\mu\text{L}$  of dimethyl sulphoxide (DMSO) and further incubated for 15 min. The absorbance was read on an automated microplate reader (Powerpack 200; Biotek Instruments) at 540 nm.

## 2.6 HPLC analyses

2.6a **Sample preparation**: A sample (30 g) of the dried leaves of *C. maculata* was placed in a Soxhlet extraction thimble and sequential extraction was carried out with *n*-hexane, dichloromethane, ethyl acetate and methanol for 24 h with each solvent. The extracts obtained were filtered to remove any plant particles and concentrated under vacuum to yield hexane, dichloromethane, ethyl acetate and methanol extracts.

For HPLC analysis, hexane, dichloromethane and ethyl acetate extracts were dissolved in acetonitrile: ethyl acetate (1:1) and the methanol extract was dissolved in methanol to make a concentration of 1 mg/mL and filtered through a 0.45  $\mu\text{m}$  PTFE syringe filter. Five  $\mu\text{L}$  of each extract was injected onto the HPLC column using an autosampler.

**2.6b Chromatographic conditions:** Appropriate separation was achieved on C<sub>18</sub> Phenomenex (250 × 4.6 mm, 5 μ) column with a gradient of ACN (solvent A), water containing 2% formic acid (solvent B) and ACN containing 1% formic acid (solvent C) using the following program: 0–10 min 5% A in B, 10–12 min 20% A in B, 12–20 min 20% A in B, 20–25 min 30% A in B, 25–30 min 40% A in B, 30–35 min 50% A in B, 35–45 min 60% A in B, 45–65 min 75% A in B, 65–70 min 100% C, 70–85 min 100% C, 85–87 min 5% A in B, 87–95 min 5% A in B. The flow rate was set at 1.5 mL/min and the analytes were detected at 280 nm. Sample injection volume was 5 μL.

**2.6c Validation of HPLC method:** Stock solutions (1 mg/mL) of standards (**1–7**, **9–30**) were prepared in ethyl acetate–acetonitrile (1:1) and diluted to appropriate concentrations for establishment of calibration curves. Six concentrations of the 29 standards were injected in triplicate and the calibration curves were constructed by plotting the peak areas against the concentration of each analyte.

The limit of detection (LOD) and limit of quantification (LOQ) under the above stated chromatographic conditions were determined on the basis of response at a signal-to-noise ratio (S/N) of 3 and 10, respectively.

Intra- and inter-day variations were used to determine the precision of the HPLC method. A sample of 30 g of dried leaves of *C. maculata* was extracted and analysed as described in the sections above. Intra-day precision was performed by triplicate extraction and analysis on a single day. The inter-day precision was carried out on 3 different days. Variations were expressed as the relative standard deviations (RSD). The recovery test was used to evaluate the accuracy of this quantitation method. Accurate amounts of the 29 analytes were added to known amounts of ethyl acetate extract that was then dissolved in ethyl acetate–acetonitrile (1:1) and analysed. The average recoveries were calculated by the following formula: recovery (%) = 100 × (amount found–original amount)/amount spiked, with RSD (%) = (SD/mean) × 100%.

### 3. Results and discussion

#### 3.1 Isolation, characterization and antileishmanial activity

The *in vitro* antileishmanial activity of *n*-hexane, dichloromethane, ethyl acetate and methanol extracts of *C. maculata* prepared by sequential maceration revealed that the hexane and methanol extracts

were active (IC<sub>50</sub> 7.0 and 7.1 μg/mL, respectively), ethyl acetate extract was moderately active (IC<sub>50</sub> 13.0 μg/mL) and the chloroform extract was inactive.

Compounds **1** and **2** were obtained after semi-preparative HPLC of yellowish crystals separated out of hexane extract of *C. maculata* leaves. <sup>1</sup>H and <sup>13</sup>C NMR of the two compounds were very similar and the molecular ion peaks in APCI MS showed a difference of 15 units indicating the loss of one methyl group. The <sup>1</sup>H NMR spectrum of **1** revealed the presence of a H-bonded hydroxyl group, a *para* substituted B ring, one aromatic A ring proton, two methoxyl groups and one *C*-methyl substituent. The combined information from the <sup>1</sup>H and <sup>13</sup>C NMR data confirmed that **1** was a flavone, unsubstituted in 3-position (δ<sub>H</sub> 6.59, δ<sub>C</sub> 105.3). Ring B protons appeared as two doublets, for two protons each (δ 7.84 and 7.01) in <sup>1</sup>H NMR. This compound was identified as 5-hydroxy-7,4'-dimethoxy-6-methylflavone (8-demethyl eucalyptin). In the spectral data of **2**, an additional signal for a *C*-methyl group (δ<sub>H</sub> 2.39) appeared and the signal of the aromatic ring A proton (δ<sub>H</sub> 6.49) disappeared. Also, the signal for C-8 was shifted downfield (δ<sub>C</sub> 89.3 in **1** and 104.1 in **2**). The structure of this compound was determined to be 5-hydroxy-7,4'-dimethoxy-6,8-dimethylflavone (eucalyptin).

Compound **3** was isolated as off-white solid from the methanol extract of leaves of *C. maculata*. A sodiated molecular ion peak was observed at *m/z* 353 [M+Na]<sup>+</sup>. A fragment peak due to loss of one methyl was present at *m/z* 316 [C<sub>13</sub>H<sub>15</sub>O<sub>9</sub>+H]<sup>+</sup>. Another fragment peak at *m/z* 202 showed the presence of sodium adduct of a hexose sugar [C<sub>6</sub>H<sub>11</sub>O<sub>6</sub>Na]<sup>+</sup>. The IR absorption band at 3368 cm<sup>-1</sup> indicated the presence of hydroxyl groups and the absorption band at 1654 cm<sup>-1</sup> was indicative of a keto group. The signal of a quaternary carbon at δ 203.4 in <sup>13</sup>C NMR spectrum confirmed the presence of a keto function in the molecule. <sup>13</sup>C NMR also showed signals due to phloroglucinol aromatic ring (between δ<sub>C</sub> 95–166) and an acetyl group. The <sup>1</sup>H NMR spectrum presented two aromatic protons (δ 6.18, d, *J* = 2.0 Hz and 5.94, d, *J* = 2.0 Hz) *meta* to each other. The presence of six <sup>13</sup>C NMR signals between δ 60 to 105 were attributable to an *O*-glycosidically linked hexose residue. The hexose residue was considered to be β-D-glucopyranose because the chemical shifts of sugar carbon were in agreement with literature data.<sup>7</sup> The coupling constant of anomeric proton (*J* = 7.4 Hz) confirmed β configuration. Acidic hydrolysis of **3** gave glucose which was identified by comparison of TLC with an authentic sample. The spectrum indicated that C-2 and C-6 were non-equivalent, i.e., signals at δ 164.8 and 161.2, respectively. The H-3

(C-3) and H-5 (C-5) signals were also non-equivalent, i.e., signals at  $\delta$  6.18 (100.6) and 5.94 (93.9), respectively. This compound was characterized as 4,6-dihydroxy-2-*O*-( $\beta$ -D-glucopyranosyl)acetophenone or myrciaphenone A.

Another compound (**4**) was isolated as a very minor component from the fractions containing myrciaphenone A. The spectral data of **4** indicated a close structural resemblance between the two compounds.  $^1\text{H}$  and  $^{13}\text{C}$  NMR showed signals for phloracetophenone core as in myrciaphenone A. The presence of a galloyl group in the structure of **4** was suggested by a two proton singlet at  $\delta$  7.10 in  $^1\text{H}$  NMR and four characteristic carbon signals ( $\delta$  108.8, 119.8, 145.1, 166.9) in  $^{13}\text{C}$  NMR spectrum. The resonances between  $\delta$  3.48 and  $\delta$  4.45 were assigned to the protons of sugar moiety. The coupling constant of the anomeric proton ( $\delta$  5.07, d,  $J = 7.6$  Hz) in the  $^1\text{H}$  NMR spectrum indicated  $\beta$  configuration and from the other chemical shifts and coupling constants of the sugar moiety, it was clear that the sugar unit was  $\beta$ -D-glucopyranose. A considerable downfield shift in the signals of H-6' ( $\delta$  4.55 and 4.45) of sugar moiety indicated the possible placement of galloyl functionality at C-6' position. Finally, the HMBC spectrum ascertained the correlation of H-6' of the  $\beta$ -glucose moiety with C-1'' of galloyl subunit. The structure of **4** was confirmed to be 4,6-dihydroxy-2-*O*-[ $\beta$ -D-(6''-galloyl)glucopyranosyl]acetophenone or myrciaphenone B.<sup>8</sup>

The other isolated compounds were characterized as quercetin-3-*O*- $\beta$ -D-xylopyranoside (**5**), myricetin-3-*O*- $\alpha$ -L-rhamnopyranoside (**6**), quercetin-3-*O*- $\beta$ -D-galactopyranoside (**7**), quercetin-3-*O*- $\beta$ -D-glucopyranoside (**8**), quercetin-3-*O*- $\alpha$ -L-rhamnopyranoside (**9**), syringic acid (**10**), gallic acid-3-methyl ether (**11**), gallic acid-4-methyl ether (**12**) and gallic acid (**13**) after the comparison of their physico-chemical and spectroscopic data with that reported in the literature (for  $^1\text{H}$  and  $^{13}\text{C}$  NMR data of compounds **1–9** refer table 1a and 1b). Except for compounds **1** and **2**, all the other compounds are reported for the first time from this species.

Isolated flavonoids and phenolic glycosides were evaluated for their antileishmanial activity *in vitro*. The results (table 2) of this assay suggested that glycosylation was necessary for high activity. The flavonoid glycosides (**6–9**) were more active than the other compounds tested whereas aglycones, **1** and **2** were inactive and less active, respectively. Amongst the flavonoid glycosides, compound **5**, where the glycone portion was a deoxy sugar i.e., xylose was much less active than the compounds containing D-glucose, D-galactose and L-rhamnose. In the case of myrciaphenone A (**3**) and B (**4**), the inhibition of promastigotes shown by **3**

**Table 2.** *In vitro* antileishmanial activity of compounds isolated from *C. maculata* extracts.\*

Compound	IC <sub>50</sub> ( $\mu\text{M}$ )
8-Demethyl eucalyptin ( <b>1</b> )	NA
Eucalyptin ( <b>2</b> )	11.0 $\pm$ 1.4
Myciaphenone A ( <b>3</b> )	10.0 $\pm$ 1.4
Myciaphenone B ( <b>4</b> )	NA
Quercetin-3- <i>O</i> - $\beta$ -D-xylopyranoside ( <b>5</b> )	24.5 $\pm$ 7.7
Myricetin-3- <i>O</i> - $\alpha$ -L-rhamnopyranoside ( <b>6</b> )	7.5 $\pm$ 2.1
Quercetin-3- <i>O</i> - $\beta$ -D-galactopyranoside ( <b>7</b> )	6.9 $\pm$ 0.3
Quercetin-3- <i>O</i> - $\beta$ -D-glucopyranoside ( <b>8</b> )	7.25 $\pm$ 0.3
Quercetin-3- <i>O</i> - $\alpha$ -L-rhamnopyranoside ( <b>9</b> )	8.5 $\pm$ 4.9
Miltefosine (Std.)	10.0 $\pm$ 3.0

\*Results are expressed as mean  $\pm$  SD of two independent experiments performed in triplicate

NA: Not active

was equivalent to that of the standard drug miltefosine whereas **4**, the galloylated counterpart of **3** was completely inactive, again suggesting a possible role of the sugar moiety in the bioactivity of compounds in this assay.

### 3.2 HPLC analyses

**3.2a Preparation of extracts:** The extraction conditions and related parameters can lead to significant differences and variations in any quantitative analyses. Therefore, it was important to select one specific method of extraction for the phytochemical analysis of *C. maculata*. Sequential Soxhlet extraction was chosen for preparing extracts as it promised maximum extraction of the compounds of low, medium and high polarities. From a 30 g sample of dried leaves of *C. maculata*, 906 mg of hexane, 1231 mg of chloroform, 1107 mg of ethyl acetate and 3689 mg of methanol extracts, respectively, were obtained after sequential Soxhlet extraction.

**3.2b Optimization of HPLC conditions:** Recently, we have reported an HPLC-PDA method for simultaneous quantitation of 19 compounds belonging to different chemical classes to facilitate quantitative comparison amongst eucalypts.<sup>15</sup> This method used a gradient of acetonitrile and 2% aqueous formic acid for the separation of compounds. In the present study, we have improved upon that method to incorporate more plant constituents so as to increase the applicability of the method. Some of the phenolic acids (**10–13**) were isolated from the methanol extract of *C. maculata*, so, the gradient program was modified to detect/quantify more

**Table 3.** Chromatographic characteristics of the compounds studied and validation results of the analytical method.

Sl. No.	Analyte	Test wavelength (nm)	Retention time (min)	Test range (ng)	Regression equation (y = mx + c)	(r <sup>2</sup> ) <sup>#</sup>	LOD* (ng)	LOQ* (ng)	Repeatability (1 day, n = 3)		Intermediate precision (3 days, n = 9)		Accuracy <sup>§</sup>	
									RSD (%)	RSD (%)	RSD (%)	RSD (%)	Recovery	RSD (%)
1	Gallic acid ( <b>13</b> )	270	4.6	100–600	y = 170.5x + 1350	0.999	8.8	25.0	1.78	2.72	98.92	1.06		
2	Gallic acid-3-methyl ether ( <b>11</b> )	270	13.5	50–500	y = 162.7x – 1177	0.999	7.2	24.3	1.28	3.33	94.66	1.06		
3	Gallic acid-4-methyl ether ( <b>12</b> )	270	16.7	50–500	y = 111.0x – 472.2	0.999	3.5	12.0	0.63	0.61	94.54	1.85		
4	Myricaphenone A ( <b>3</b> )	284	17.0	500–1000	y = 179.9x – 295.2	0.999	10.1	35.3	0.99	1.33	94.53	1.31		
5	Syringic acid ( <b>10</b> )	270	18.0	50–500	y = 151.6x – 424.7	0.999	20.7	58.4	0.07	1.18	97.28	3.22		
6	Myricaphenone B ( <b>4</b> )	284	19.5	50–500	y = 80.75x – 1255	0.999	11.2	28.3	ND	ND	ND	ND		
7	Quercetin-3-O-β-D-rhamnopyranoside ( <b>9</b> )	350	20.6	200–700	y = 85.15x – 189.3	0.999	17.9	54.0	3.04	3.50	101.06	3.17		
8	Quercetin-3-O-β-D-galactopyranoside ( <b>7</b> )	350	21.0	200–700	y = 105.3x – 1297	0.999	33.4	95.2	0.64	3.64	107.71	0.0		
9	Quercetin-3-O-β-D-xylopyranoside ( <b>5</b> )	350	22.8	200–700	y = 106.1x + x 91.46	0.999	16.2	48.2	3.61	3.94	102.33	1.21		
10	Myricetin-3-O-β-D-rhamnopyranoside ( <b>6</b> )	350	25.5	200–700	y = 82.86x – 3395	0.999	23.1	69.3	0.62	0.38	105.41	1.18		
11	8-Demethyl eucalyptin ( <b>1</b> )	328	55.3	500–1000	y = 241.1x – 5702	0.999	21.7	58.7	2.43	0.39	91.73	2.16		
12	Eucalyptin ( <b>2</b> )	328	58.8	500–1000	y = 263.1x + 7802	0.999	29.3	97.8	2.88	4.55	94.94	1.03		

<sup>#</sup>r<sup>2</sup> is correlation coefficient of each calibration curve


\*LOD and LOQ were estimated by successively diluting the standard solutions, considering a signal-to-noise ratio of 3 and 10, respectively

<sup>§</sup>Spiked amount (ng) for each analyte is the highest amount used in the test range (column 5); ND, not determined

compounds of this class (**15–17**). Particularly, the initial ratio of the stronger solvent i.e., ACN was reduced and gradient time was increased so that highly polar phenolic acids could be separated.

After trying several solvent systems and gradients, a solvent system consisting of ACN (solvent A), water with 2% formic acid (solvent B), ACN with 1% formic acid (solvent C) in gradient mode (as described in ‘chromatographic conditions’) was found to be optimum. Initially, a binary gradient of A and B was used from 0 to 65 min. This gradient allowed the separation of eucalyptin (**2**), a methylated flavonoid and jensenone (**23**),

a formylated phloroglucinol which, despite their structural differences, were eluting at same RT in several other solvent systems and gradient programs (though baseline resolution was not achieved in this gradient but owing to the differences in  $\lambda_{\max}$ , 328 for eucalyptin and 266 for jensenone, qualitative analysis of samples containing both the compounds was possible). From 65 to 70 min, the proportions of solvents A and B were decreased and that of C was increased until 100% at 70 min. The 100% concentration of C was maintained for 15 min. This allowed the resolution of euglobals (**25**, **27–30**) and sideroxylonal A (**26**) that otherwise was not



**Figure 2.** HPLC chromatogram (at 280 nm) of (a) mixed standard solution, **13**: gallic acid (4.63 min); **14**: protocatechuic acid (9.76 min); **11**: gallic acid-3-methyl ether (13.52 min); **15**: chlorogenic acid (16.60 min); **12**: gallic acid-4-methyl ether (16.78 min); **3**: myricaphenone A (17.04 min); **16**: caffeic acid (17.63 min); **10**: syringic acid (18.03 min); **4**: myricaphenone B (19.53 min); **9**: quercetin-3-*O*- $\alpha$ -L-rhamnopyranoside (20.60 min); **7**: quercetin-3-*O*- $\beta$ -D-galactopyranoside (21.00 min); **5**: quercetin-3-*O*- $\beta$ -D-xylopyranoside (22.8 min); **6**: myricetin-3-*O*- $\alpha$ -L-rhamnopyranoside (25.50 min); **17**: 2-hydroxy cinnamic acid (26.88 min); **18**: syncarpic acid (30.08 min); **19**: flavesone (50.99 min); **20**: miniatone (52.43 min); **1**: 8-demethyl eucalyptin (55.27 min); **21**: grandinol (56.63 min); **22**: 8-demethyl kalmiatin (58.39 min); **2**: eucalyptin (58.88 min); **23**: jensenone (59.14 min); **24**: leptospermone (63.06 min); **25**: euglobal G1 (77.52 min); **26**: sideroxylonal A (77.79 min); **27**: euglobal G2 (78.36 min); **28**: euglobal B1-1 (78.95 min); **29**: euglobal G3 (79.32 min) and **30**: euglobal G4 (80.09 min); (b) hexane extract; (c) ethyl acetate extract.

achieved. Another mobile phase with solvents C and B (keeping the gradient program same as above) was tested but eucalyptin and jensenone were eluted as a single peak in this system. The gradient program with the solvents A, B and C was used for all analyses. One disadvantage of this method is the co-elution of quercetin-3-*O*- $\beta$ -D-galactopyranoside (**7**) and quercetin-3-*O*- $\beta$ -D-glucopyranoside (**8**). For the quantitation of **7** and **8**, calibration curve of **7** was constructed and both **7** and **8** were quantified in total.

**3.2c Method validation:** The proposed method was validated to determine the linearity, LOD, LOQ, intra- and inter-day precisions and accuracy. The calibration curves for compounds (**1–7**, **9–13**) were obtained with concentrations in six increments. The correlation coefficient values ( $r^2 = 0.999$ ) indicated the appropriate correlation between concentration and the corresponding peak areas. LOD and LOQ for all the analytes were determined by diluting the standard stock solutions of the corresponding compounds sequentially. The LOD (S/N = 3) and LOQ (S/N = 10) for the compounds quantified were in the range of 3.5–33.4 ng and 12–97.8 ng, respectively (table 3). The HPLC method developed showed good reproducibility for the quantitation of 12 compounds, with intra- and inter-day variations of these compounds less than 3.6% (RSD) and 4.6% (RSD), respectively. Also, this method was found to be accurate with the overall recovery of 91.7–107.7% (RSD range 0.0–3.22%) (table 3). These results establish that the developed method is sensitive, precise and accurate with respect to the plant constituents studied and can be applied more widely for qualitative and quantitative analysis of eucalypt matrices.

**3.2d Analysis of samples and quantitation:** The extracts of *C. maculata* leaves prepared by sequential Soxhlet extraction were analysed by the developed method. Of the 29 compounds used in method development, only two were detected in hexane and chloroform extracts and ten compounds were found to be present in ethyl acetate and methanol extracts. The HPLC chromatogram of 29 mixed standards along with the chromatograms of hexane and ethyl acetate extracts are shown in figure 2 and the contents of the detected constituents in the respective extracts are presented in table 4.

The results of the HPLC quantitation were consistent with the biological activity results. In the *in vitro* antileishmanial assay, hexane and methanol extracts were most active. In case of hexane extract, demethyl eucalyptin (**1**) and eucalyptin (**2**) were found to be the major constituents, present at 2.16 and 2.87%, respectively. The methanol extract showed the presence of active flavonoid glycosides. Myrciaphenone A (**3**, IC<sub>50</sub> 10  $\mu$ M) was found to be the major constituent of the ethyl acetate extract. Myrciaphenone B could not be detected in any of the extracts up to a loading of 5000 ng. None of the active (or inactive) compounds could be detected in the chloroform extract.

### 3.3 Chemotaxonomical importance of the study

The genus *Eucalyptus* encompasses about 800 species grouped into 13 different informal subgenera.<sup>17</sup> W E Hillis studied the variation of the polyphenol content in different eucalypts as a marker in their chemosystematic studies.<sup>18–22</sup> More recently, Eschler *et al.* asserted that formylated phloroglucinol compounds (FPCs) are

**Table 4.** The contents of the studied compounds in three extracts of dry leaves of *C. maculata*.

Sl. No.	Compound	Content (%) <sup>a</sup>		
		Hexane extract	Ethyl acetate extract	Methanol extract
1	Gallic acid ( <b>13</b> )	–	3.17 $\pm$ 0.09	1.20 $\pm$ 0.03
2	Gallic acid-3-methyl ether ( <b>11</b> )	–	–	1.73 $\pm$ 0.06
3	Gallic acid-4-methyl ether ( <b>12</b> )	–	–	1.95 $\pm$ 0.01
4	Myrciaphenone A ( <b>3</b> )	–	8.26 $\pm$ 0.78	1.38 $\pm$ 0.14
5	Syringic acid ( <b>10</b> )	–	–	2.66 $\pm$ 0.03
6	Quercetin 3- <i>O</i> - $\beta$ -D-rhamnopyranoside ( <b>9</b> )	–	1.71 $\pm$ 0.16	0.41 $\pm$ 0.05
7	Quercetin 3- <i>O</i> - $\beta$ -D-galactopyranoside ( <b>7</b> ) <sup>b</sup>	–	0.49 $\pm$ 0.02	0.46 $\pm$ 0.03
8	Quercetin 3- <i>O</i> - $\beta$ -D-xylopyranoside ( <b>5</b> )	–	0.32 $\pm$ 0.01	0.05 $\pm$ 0.01
9	Myricetin 3- <i>O</i> - $\beta$ -D-rhamnopyranoside ( <b>6</b> )	–	2.24 $\pm$ 0.20	0.40 $\pm$ 0.06
10	8-Demethyl eucalyptin ( <b>1</b> )	2.16 $\pm$ 0.15	–	–
11	Eucalyptin ( <b>2</b> )	2.87 $\pm$ 0.26	–	–

<sup>a</sup>Content = mean  $\pm$  s.d. ( $n = 3$ ); <sup>b</sup>total content of **7** and **8** based on the calibration curve of quercetin 3-*O*- $\beta$ -D-galactopyranoside (**7**); –, not detected

found more abundantly in the sub-genera *Symphomyrtus* and *Eudesmia* whereas there is a notable lack of FPCs in the sub-genera *Monocalyptus*, *Idiogenes*, *Blakella* and several species of *Corymbia*.<sup>23</sup> So, to confirm the presence or absence of FPCs in *Corymbia maculata*, we undertook phytochemical investigations of this plant.

Our results show that there is a complete absence of the tested FPCs in all four extracts of *C. maculata*. Also, none of the tested 'non-formylated' phloroglucinols (miniatone and triketones) could be detected in these extracts. Though this study was done on a single bulk sample of *C. maculata* originating from four individual trees, it supports the results of earlier experiments done by Eschler *et al.*<sup>23</sup>

#### 4. Conclusions

The phytochemical screening of *C. maculata* resulted in the isolation of thirteen compounds from hexane and methanol extracts of the dried leaves. Flavonoid glycosides and a phloroglucinol glycoside were the active antileishmanial compounds. The developed HPLC–PDA method can be applied for the simultaneous quantitation of phytoconstituents of different chemical classes. This method was applied to detect and quantify twelve compounds in the extracts of *C. maculata* leaves.

#### Acknowledgements

Authors thank the Director, NIPER for support and Dr Ian Wallis for assistance in collecting *Corymbia maculata* foliage.

#### References

1. WHO technical report series, Leishmaniasis (2010) Retrieved from WHO website: [http://whqlibdoc.who.int/trs/WHO\\_TRS\\_949\\_eng.pdf](http://whqlibdoc.who.int/trs/WHO_TRS_949_eng.pdf)
2. Bharate S B, Khan S I, Yunus N A M, Chauthe S K, Tekwani B L, Jacob M R, Khan I A and Singh I P 2007 *Bioorg. Med. Chem.* **15** 87
3. Bharate S B, Khan S I, Tekwani B L, Jacob M R, Khan I A and Singh I P 2008 *Bioorg. Med. Chem.* **16** 1328
4. Sidana J, Singh S, Arora S K, Foley W J and Singh I P 2011 *Fitoterapia* **82** 1118
5. Takahashi T, Kokubo R and Sakaino M 2004 *Lett. Appl. Microbiol.* **39** 60
6. Lambertson J A 1964 *Aust. J. Chem.* **17** 692
7. Suksamrarn A, Eiamong S, Piyachaturawat P and Byrne L T 1997 *Phytochemistry* **45** 103
8. Chosson E, Chaboud A, Chulia A J and Raynaud J 1998 *Phytochemistry* **47** 87
9. Lu Y and Foo L Y 1997 *Food Chem.* **59** 187
10. David J M, Cruz F G, Guedes M L S and Chavez J P 1996 *J. Braz. Chem. Soc.* **7** 115
11. Wettasinghe M, Shahidi F, Amarowicz R and Abou-Zaid M M 2001 *Food Chem.* **75** 49
12. Ali Z, Ahmad V U, Zahid M and Tareen R B 1998 *Phytochemistry* **48** 1271
13. Saxena G, McCutcheona A R, Farmerb S, Towersa G H N and Hancock R E W 1994 *J. Ethnopharmacol.* **42** 95
14. Singh P P, Ambika and Chauhan S M S 2009 *Food Chem.* **114** 1069
15. Sidana J, Foley W J and Singh I P 2012 *Phytochem. Anal.* **23** 483
16. Mosmann T 1983 *J. Immunol. Methods* **65** 55
17. Brooker M I H 2000 *Aust. Syst. Bot.* **13** 79
18. Hillis W E 1966 *Phytochemistry* **5** 1075
19. Hillis W E 1967a *Phytochemistry* **6** 259
20. Hillis W E 1967b *Phytochemistry* **6** 275
21. Hillis W E 1967c *Phytochemistry* **6** 373
22. Hillis W E 1967d *Phytochemistry* **6** 845
23. Eschler B M, Pass D M, Willis R and Foley W J 2000 *Biochem. Syst. Ecol.* **28** 813